ALKERMES | ALKS - Operating Profit


ALKERMES reported $89.08M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
AbbVie USD 5.72B 1.98B Jun/2025
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
ALKERMES USD 89.08M 3.9M Sep/2025
Amgen USD 4.43B 1.77B Sep/2025
Biogen USD 659.6M 192.2M Sep/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Bristol-Myers Squibb USD 3.64B 135M Sep/2025
Eli Lilly USD 8.39B 1.37B Sep/2025
Gilead Sciences USD 3.51B 810M Sep/2025
Ionis Pharmaceuticals USD -160.18M 300.02M Sep/2025
J&J USD 5.59B 1.81B Dec/2025
Malin Corporation EUR -1.1M 400K Dec/2024
Merck USD 6.55B 189M Sep/2025
Neurocrine Biosciences USD 239.3M 93.7M Sep/2025
Otsuka Holdings JPY 168.82B 61.81B Sep/2025
Pfizer USD 652M 3.67B Sep/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Vertex Pharmaceuticals USD 1.24B 84.6M Sep/2025